Global expansion BVBLUE is a rapidly adopted CLIA waived rapid sialidase test for bacterial vaginosis with over 7 million tests sold worldwide, signaling strong international demand and opportunities for domestic and cross-border distributor partnerships.

Distributor opportunities The company explicitly seeks distributors to add BVBLUE to assortments, presenting a clear channel for sales partnerships in new regions and existing markets with potential for scaled distribution and co-marketing.

Healthcare fit As a medical equipment product with CLIA waiver, BVBLUE offers a low-complexity, rapid diagnostic option that can fit into point-of-care settings and streamline BV screening workflows, appealing to clinics, hospitals, and outpatient networks.

Competitive positioning With a focus on rapid, single-test turnaround and minimal regulatory burden, BVBLUE differentiates from more complex diagnostics, enabling partners to market a fast, affordable solution to BV management.

Revenue potential A revenue range of 1–10 million indicates a scalable, mid-market profile with room for growth through expanded distribution, international license agreements, and bundled offerings with related women's health diagnostics.